BA
DXCM icon

Bivin & Associates’s DexCom DXCM Stock Holding History

Bivin & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$27K Hold
360
– – 0.03% 104
2022
Q1 		$46K Buy
360
+200
+125% +$21.9K 0.04% 82
2021
Q4 		$21K Buy
+160
New +$23K 0.02% 141

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bivin & Associates's DXCM Position: Q2 2022 in Review

Bivin & Associates held its DexCom (DXCM) position steady in Q2 2022 at 360 shares worth $27K. The position accounts for 0.03% of the portfolio, ranked #104.

Bivin & Associates first reported a position in DXCM in Q4 2021 and has held it in 3 quarters since. The position peaked at $46K in Q1 2022. 798 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

  • Bivin & Associates held 360 shares of DexCom worth $27K as of Q2 2022.
  • Bivin & Associates left its DexCom share count unchanged in Q2 2022.
  • DexCom made up 0.03% of Bivin & Associates's portfolio in Q2 2022, its #104 holding.
  • Bivin & Associates first reported a position in DexCom in Q4 2021 and has held it in 3 quarters since.
  • Bivin & Associates's DexCom position peaked at $46K in Q1 2022.
  • 798 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.